LUPIN

Lupin has returned to growth with strong US generics performance and improved margins. The company’s respiratory and cardiovascular portfolios continue to scale well globally. Regulatory challenges have eased, allowing faster product approvals. With a strong pipeline and strategic cost reductions, Lupin is better positioned for sustained profitability. Investors should watch currency fluctuations and FDA developments.